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 ABSTRACT 
 Bovine udder infections induce a variety of changes 
in gene expression of different growth factors that may 
suggest their possible role in glandular tissue protection 
or repair processes. Growth factors and also chemo-
kines and cytokines may act synergistically to increase 
the infiltration of neutrophils and macrophages to pro-
mote angiogenesis, fibroplasia, matrix deposition, and, 
ultimately, re-epithelialization. Considering the vast 
applications, typically in human medicine, of platelet 
concentrate (PC) and its ease of preparation, the aim 
of our study was to evaluate an alternative therapy to 
stimulate the regeneration of glandular tissue, admin-
istering a concentration in excess of the growth factors 
contained in the PC. In each one of the 3 farms exam-
ined in the trial, PC was prepared from donor cows in 
good health, free from infections, and with no records 
of medications administered during the previous 2 mo. 
The platelet produced in one farm was used only for 
treating the cows of the same farm in a heterologous 
way. A total of 229 mastitic quarters were divided in 3 
groups: antibiotic group (treated with intramammary 
antibiotic), antibiotic and PC group (treated intra-
mammarily with antibiotics in association with PC), 
and PC group (treated with intramammary PC alone). 
The diagnosis of mastitis was based on somatic cell 
count and bacteriological evaluation of the milk from 
the affected quarter. Platelet concentrate, alone or in 
association with antibiotic, was used for 3 consecutive 
days as an unconventional therapy in bovine acute and 
chronic mastitis. Our data show that the associated 
action of antibiotic and PC performed significantly 
better than the antibiotic alone, either for the recov-
ery of the affected mammary quarters or for somatic 
cell count reduction. In the same way, the association 
antibiotic plus PC showed significantly fewer relapses 
compared with the antibiotic alone, either for acute 
or chronic mastitis. The treatment with only PC did 
not show statistically significant differences compared 
with both antibiotic alone or associated treatment for 
acute mastitis, and it was better than the use of only 
antibiotic for chronic mastitis. Our results show that 
PC alone may be useful for a quick resolution of the 
inflammatory response, playing a role in limiting the 
tissue damage to the mammary gland parenchyma and 
reducing the recurrence rates. 
 Key words:  platelet concentrate , mastitis , growth 
factor , antibiotic , relapse 
 INTRODUCTION 
 An effective mastitis control program should be 
based on the containment of new infections through 
correct milking management, careful aseptic practices, 
and reducing the duration of existing infections with 
lactation antibiotic therapies, dry cow therapy, and by 
culling of refractory animals. For these reasons, masti-
tis is the most costly infectious disease of dairy cattle. 
Indeed, in addition to decreased production, economic 
losses associated with clinical mastitis include cost of 
treatment, extra labor, and an increased rate of cow 
replacement (Bartlett et al., 1990). Although antibi-
otics are very useful to treat infections, they do not 
directly protect the gland from being damaged (Zhao 
and Lacasse, 2008). Moreover, mastitis, besides being 
an animal welfare issue, is also a food safety problem 
because it should be taken into account that dairy cows 
produce milk for human consumption. This assumption 
makes urgent to expand the prophylaxis interventions 
based on management, livestock hygiene, respect for 
animal welfare, and the development of alternative 
remedies that can replace or support those currently in 
use. In addition to the use of antibiotics, other thera-
pies, aimed at reducing udder tissue damages, may 
be a cost-effective way to reduce the losses caused by 
mastitis (Zhao and Lacasse, 2008).
 Studies performed in organic farms, which represent 
only a small part of dairy farming, show that in Germa-
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ny and the United Kingdom 34 and 51%, respectively, 
of clinical mastitis cases were treated with homeopathic 
remedies (Hovi and Roderick, 2000; Krömker and Pfan-
nenschmidt, 2005). So far, only a few papers on the use 
of homeopathy as a treatment strategy against mastitis 
have been published, mainly because many of these 
studies have often been criticized for their inadequate 
scientific approach (Cucherat et al. 2000).
Werner et al. (2010) showed a therapeutic effect 
of homeopathic treatment only in cases of mild and 
moderate clinical mastitis that were caused by envi-
ronmental pathogens or those with no provable patho-
gen in the milk sample at d 0. Therefore, exclusion 
of mastitis caused by udder-associated pathogens in 
the dairy herd in combination with an improved farm- 
and cow-specific diagnostic procedure is an important 
precondition when using the homeopathic treatment 
strategy. For this reason, it would be important to 
identify alternatives to the use of antibiotics, especially 
knowing that mastitis induces disruption of the normal 
secretory functions of the mammary gland by reducing 
the number of epithelial cells and their activity. Mam-
mary epithelial cells are able to produce a variety of 
inflammatory mediators such as cytokines, chemokines, 
host-defense peptides, and arachidonic acid metabolites 
(Sharma et al., 2011). An array of immunoregulatory 
cytokines are likely involved in mediating the immune 
responses to mastitis and have been proposed as poten-
tial preventives for mastitis (Blecha, 1991; Kehrli et al., 
1991). Indeed, infection of bovine udders induces a va-
riety of changes in gene expression, including a decrease 
in α-LA and casein mRNA and, on the contrary, an 
increase in mRNA of several growth factors, including 
acidic fibroblast growth factor, basic fibroblast growth 
factor, epidermal growth factor, transforming growth 
factor (TGF) α, IGF-I, and IGF-II. These results sug-
gest a possible role of peptide growth factors in tissue 
protection or repair processes (Sheffield, 1997). For this 
reason, a different approach for the treatment of masti-
tis might be to stimulate the regeneration of glandular 
tissue, providing a supraphysiological concentration of 
growth factors through the use of platelet concentrate 
(PC) as an alternative therapy. Platelets, in fact, 
contain a significant amount of growth factors, accu-
mulated in their α-granules, which may be useful in 
the healing process. Transforming growth factor β1 and 
TGF-β2, the platelet-derived growth factors (PDGF; 
PDGF-AA, PDGF-BB, and PDGF-AB), IGF-I, epider-
mal growth factor, and hepatocyte growth factor are 
very important for the healing process. Platelets secrete 
growth factors and also chemokines and cytokines and 
release active metabolites, each of which could have a 
positive influence in clinical situations requiring rapid 
healing and tissue regeneration. Indeed, these growth 
factors act synergistically to increase the infiltration of 
neutrophils and macrophages, and to promote angio-
genesis, fibroplasia, matrix deposition, and, ultimately, 
re-epithelialization (Anitua et al., 2004).
Because several in vitro studies have shown a direct 
dose-response influence of many growth factors on 
cell migration, cell proliferation, and matrix synthesis 
(Abrahamsson, 1997; Thomopoulos, 2005; Costa et al., 
2006; Haupt et al., 2006), it has been suggested that 
the local administration of increased concentrations of 
these growth factors through the use of PC could op-
timize the local healing environment and thus enhance 
the ability of biologically compromised tissues to gener-
ate a repair response (Marx, 2004).
In human medicine, maxillofacial surgery, dental im-
plant surgery, orthopedic surgery and bone reconstruc-
tion, muscle and tendon repair, reversal of skin ulcers, 
retinal hole repair in eye surgery, and cosmetic surgery 
are situations where autologous platelet concentrate 
accelerate healing (Anitua et al., 2004). In veterinary 
medicine, little clinical information exists about the 
application of platelet-rich plasma. It is mainly used 
for equine tendon repair (Georg et al., 2010) and its 
application has also been reported on intestinal wound 
healing in pigs (Fresno et al., 2010) and on a large 
cutaneous lesion in a dog (Kim et al., 2009).
In these circumstances, it seemed interesting to carry 
out a study based on the concept of regenerative medi-
cine for the control of bovine mastitis by the use of PC. 
Considering the efficacy of PC mostly in human medi-
cine, the absence of reports in the scientific literature 
on the use of PC in bovine mastitis, and its ease of 
preparation, the aim of our study was to evaluate the 
effect of PC administration, alone or associated with 




The study was performed between January and April 
2012, which is supposed to be the most stable climatic 
period in Italy, with a low rain rate and temperature 
between 0 and 10°C.
Farms. The experiment was carried out in 3 farms 
managed in a cubicle yard and divided into different 
lactation groups. Herd size varied from 150 to 300 cows 
in lactation. One herd was managed by milking robots, 
whereas the other 2 followed a twice-daily milking regi-
men. Cows suffering from mastitis were identified at 
milking time by the farmer or by the robot control pro-
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gram. Mastitis diagnosis was subsequently confirmed 
by the veterinarian enrolled in the study for examining 
the cows for inclusion in the trial.
Mastitis Diagnosis. The careful diagnosis of mas-
titis took into account the changes in the milk (chunks, 
flakes, clots, or blood), the changes in the condition 
of the affected quarter (swelling, redness, hardening, 
heat, or pain), and the general condition of the animals. 
Depending on symptoms and milk analysis, acute and 
chronic mastitis were diagnosed. Acute mastitis is char-
acterized by visible signs, such as abnormal milk (flakes, 
clots, decrease in milk production, and sometimes milk 
discoloration) and hot, swollen, and painful quarters. 
Milk production decreases and the milk composition is 
considerably altered (Harmon, 1994). Chronic mastitis 
is described as repeated cases of mastitis where the 
cow fails to respond successfully to treatment, although 
clinical symptoms may disappear temporarily (Akers, 
2002). In our study, cows were considered affected by 
chronic mastitis when the SCC was >500,000 cells/mL 
for 3 consecutive months (Rahman et al., 2012) in a 
quarter-milk sample. Cows needing general antibiotic 
treatments were excluded from this study.
Animals. A total of 229 animals were enrolled in 
this study. On each farm, cows that fulfilled the inclu-
sion criteria were randomly allocated into 3 groups: 
(1) antibiotic (control) group (66 quarters), which was 
treated with intramammary antibiotic; (2) antibiotic 
and PC group (80 quarters), which was treated with 
intramammary antibiotics in combination with PC 
(associated treatment); or (3) PC group (83 quarters), 
which was treated with PC alone. Each mastitic udder 
quarter was enrolled only once.
Preparation of Platelet Concentrate
Collection of Blood. Because it takes time for PC 
preparation and to have the prescribed amount of PC 
immediately available for treatment as soon as a mas-
titis case was diagnosed, a stock of PC was prepared 
and kept separated for each one of the 3 farms involved 
in the experiment. In this way, the PC obtained from 
blood donor cows, in good health, free from infections 
and without any medication during the previous 2 mo, 
was used in a heterologous way for treating only the 
mastitic cows belonging to the same farm of the blood 
donor cows.
After surgical scrub preparation of a few centimeters 
of skin around the subcutaneous mammary vein, 450 
mL of blood was collected in ad hoc Terumo blood bags 
(Terumo Srl, Rome, Italy) containing citrate-phosphate-
dextrose-adenine (CPDA-1) using the 16-gauge needle 
provided with the bags. The bags were transported at 
+4°C to the laboratory within 2 h of collection and 
immediately processed.
Double Centrifugation Method. All separation 
steps were performed under a horizontal laminar flow 
hood in aseptic conditions. To prepare the PC, the 
blood was drawn into sterile Falcon tubes of 50 mL 
each (EuroClone SpA, Milan, Italy). The tubes were 
centrifuged at 100 × g for 30 min at 4°C. This caused 
separation of the blood into 3 components: red blood 
cells at the lowest level, “buffy coat” in the middle 
layer, and platelet-rich plasma (PRP) in the upper 
layer. Afterward, the PRP was carefully aspirated 
and distributed in new 50-mL tubes and centrifuged 
again at 1,500 × g for 10 min at 4°C to obtain the 
platelet pellet and the poor platelet plasma (PPP) at 
the upper layer. Afterward, two-thirds of the volume of 
PPP was aspirated for later use and the pellet mixed 
in the residual PPP volume to allow for platelet count 
before the final dilution with PPP to obtain PC at 
a standard concentration of 1 × 109 platelet/mL. All 
platelet counts on peripheral blood, PRP, and PC were 
performed using a HeCo Vet automatic hematology 
analyzer (SEAC, Florence, Italy).
The total amount of PC obtained for each donor was 
aliquoted in 5 mL ready-to-use doses that were stored 
in syringes. The syringes were then frozen at −80°C 
and thawed at 37°C 3 times (Zimmermann et al., 2003) 
to allow the release of platelet-derived factors. The PC 
was subjected to bacteriological examination to verify 
its sterility. Syringes containing the PC dose were kept 
frozen at −20°C until use.
Indicators of Udder Inflammation
SCC. Somatic cell count was performed starting at 
d 0, and then at d 7, 14, and 30 of treatment. Somatic 
cell counts were assessed by fluorometric measurement 
on a DeLaval Cell counter (DeLaval International AB, 
Tumba, Sweden) following International Dairy Federa-
tion procedures (IDF, 1995). The SCC is expressed as a 
linear score (LS), which is a logarithmic function that 
transforms the number of somatic cells into a linear 
scale:
LS = log2 (no. of cells: 100) + 3.
Bacteriological Analysis. Quarter milk samples 
for bacteriological assays were collected before milking 
using an aseptic procedure at the start of the treatment 
(d 0) from each affected quarter. Bacteriological analy-
ses were performed by plating on blood agar with esculin 
and Baird-Parker rabbit plasma fibrinogen (RPF) agar. 
After incubation at 37°C for 48 h, the colonies grown 
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in pure culture were identified by conventional bacte-
riological methods on the basis of morphological and 
biochemical characteristics by routine methods accord-
ing to the National Mastitis Council (1999).
Intramammary Administration of Antibiotics  
and Platelet Concentrate
All herd milking procedures included premilking 
cleaning of the teats with detergent and single-use pa-
per towels and teat dipping at the end of milking with 
an approved teat disinfectant. All cows were treated 
after milking as hereafter described. After thawing, the 
syringe in which PC was stored was connected to a 
sterile disposable teat cannula to help the intramam-
mary inoculation of PC through the teat canal. The 
antibiotic for local use, chosen on the basis of an an-
tibiogram test, was inoculated using the same proce-
dure, according to manufacturer indications. Following 
inoculation, the udder was gently rubbed with upward 
movement of the hands to distribute the product. In 
the case of treatment of antibiotic and PC, the latter 
was administered first.
After a preliminary study with different doses of PC 
(5, 10, and 20 mL), no significant differences were de-
tected in the results (data not shown), so we decided 
to perform this study with 5 mL of PC. Five milliliters 
of PC alone or associated with antibiotic or antibiotic 
alone was administrated for 3 consecutive days, depend-
ing on the treatment group. After these treatments, 
teat dipping was performed.
Classification of Outcomes
Treatment outcomes were assessed by clinical and 
laboratory evaluations. Clinical improvement was de-
fined as the return of quarter and milk secretion to 
normal. It was assessed by visual observation of milk 
composition and palpation of the udder. Rate of relapse 
was, furthermore, evaluated. A relapse was defined as 
a clinical mastitis event that occurred in the enrolled 
quarter from the last time of examination (30 d after 
the treatment) until the end of the same lactation. 
Good improvement of an udder quarter was defined as 
having clinically progressed and showing, at the time of 
last examination, an SCC value decreasing by at least 
3 LS points compared with the starting value at time 0.
Statistical Analysis
The collection efficiency of platelets for each PC 
obtained by double centrifugation tube methods was 
analyzed using the following formula (Weibrich et al., 
2005):
 
efficiency for platelet collection
platelet count L in PC
=
×μ volume of PC
platelet count in whole blood L volume of whoμ × le blood
.
 
Data were collected in a database and analyzed by 
the general linear model for repeated measures on 
GraphPad InStat 3.00 for Windows software (Graph-
Pad Software Inc., La Jolla, CA). The between-subjects 
factor was represented by treatments (3 levels) and the 
within-subjects factor was represented by sampling 
time (4 levels) and the model applied was a full facto-
rial, with polynomial contrasts for within-subjects fac-
tor. The statistical analysis of bacteriological data and 
rate of relapses was conducted using the Fisher exact 
test. For all tests, differences were considered statisti-
cally significant at P ≤ 0.05.
RESULTS
Platelet Collection Efficiency
The platelet collection efficiency for the PC obtained 
by the double centrifugation protocol was (mean ± SD) 
10.9 ± 2.3%, indicating that 10.9 ± 2.3 mL of PC at 
the concentration of 1 × 109 platelet/mL was obtained 
from 100 mL of blood.
SCC and Bacteriological Assay
Of the 229 cows in our study, 144 were classified as 
affected by acute mastitis and 85 by chronic mastitis. 
At time 0, the average value of SCC was 11 × 106 cells/
mL with a standard deviation of 4.4 × 106 cells/mL in 
acute mastitis and 6.14 × 106 cells/mL with a standard 
deviation of 6.0 × 106 cells/mL in chronic mastitis.
The allocation of the enrolled quarters into the 3 dif-
ferent experimental groups was performed randomly at 
the treatment start before the results of the bacterio-
logical assays. With the exception of the esculin-positive 
streptococci group, which was less represented in the 
acute mastitis antibiotic-treated group, the distribution 
of the enrolled quarters positive for bacterial growth 
was random and not significantly different among the 
treatment groups either with acute or chronic mastitis, 
as shown in Tables 1 and 2.
Treatments
Results of the treatments with antibiotic alone, an-
tibiotic and PC, and only PC are reported in Table 
3, which shows the percentage of quarters with an 
improvement of at least 3 LS points less than the start-
Journal of Dairy Science Vol. 97 No. 10, 2014
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ing value and the rate of relapse. Statistical analysis 
showed that the associated treatment of antibiotic and 
PC had significantly superior performance (P < 0.05) 
compared with antibiotic alone relative to the improve-
ment of mammary mastitic quarters and to the rate 
of relapse. The treatment with PC only did not show 
statistically significant differences compared with both 
antibiotic alone and the associated treatment for the 
acute mastitis group, whereas it was significantly better 
(P < 0.05) than antibiotic alone for the chronic mastitis 
group relative to the number of improved quarters and 
relapses.
Table 4 shows the values and the significant differ-
ences in the SCC expressed as LS at the different time 
points during treatments for acute and chronic mastitis 
with different protocols. These data illustrate that the 
starting LS values of the associated treated quarters 
were the highest (worst) compared with the other groups 
and that at 30 d after treatment (T30), a statistically 
significant difference (P < 0.05) existed between the 
associated treatment group compared with the antibi-
otic or PC alone groups. The associated treatment, in 
fact, decreased the mean value of LS more significantly 
than other treatments, whereas the treatment with PC 
or antibiotic performed similarly. Moreover, either for 
acute or chronic mastitis, the improvement in LS values 
in the PC treatment group started to be evident at d 
14 from the beginning of treatment with respect to the 
antibiotic alone and at d 7 with respect to the associ-
ated groups. The final outcome of the PC treatment 
alone and the antibiotic treatment was similar.
DISCUSSION
The extensive use of antibiotics implies an increased 
risk of residues in milk and, in the common perception, 
the development of antibiotic resistance. However, scien-
tific evidence does not support a widespread, emerging 
resistance among mastitis pathogens to antibacterial 
drugs, but definitive conclusions on resistance patterns 
of mastitis pathogens are difficult, given the limitations 
of the data presented in the literature (Erskine et al., 
2004). The maintenance of consumer confidence, by 
satisfactory levels of animal welfare and restricted use 
of antibiotics, continues to be an important matter. In 
these contexts, we explored a different approach for 
mastitis therapy using PC as an alternative treatment. 
The experimental approach is based on the regenera-
tive properties of the PC described in the literature (for 
a review, see Anitua et al., 2004).
Table 1. Allocation of enrolled quarters with acute mastitis positive to bacterial growth into 3 experimental 
groups 
Item
Total no. of  
quarters (%)
Treatment [no. (%)]
Antibiotic Antibiotic and PC1 PC
Quarters
 Total treated 144 (100) 40 (27.78) 53 (36.80) 51 (35.42)
 Positive to bacterial growth 91 (63.19) 25/40 (62.5)a 38/53 (71.7)a 28/51 (54.9)a
Microorganism
 Esculin-positive streptococci 37/91 (40.66) 5 (14)a 17 (46)b 15 (40)b
 CNS 19/91 (20.88) 7 (36.84)a 8 (42.11)a 4 (21.05)a
 Escherichia coli 25/91 (27.47) 9 (36)a 10 (40)a 6 (24)a
 Streptococcus dysgalactiae 6/91 (6.79) 2 (33.33)a 1 (16.67)a 3 (50)a
 Coagulase-positive staphylococci 2/91 (2.2) 1 (50)a 1 (50)a —
 Enterobacteriaceae 2/91 (2.2) 1 (50)a 1 (50)a —
a,bDifferent superscript letters within a row indicate significant differences (P < 0.05).
1PC = platelet concentrate.
Table 2. Allocation of enrolled quarters with chronic mastitis positive to bacterial growth into 3 experimental groups 
Item
Total no. of 
quarters (%)
Treatment [no. (%)]
Antibiotic Antibiotic and PC1 PC
Quarters
 Total treated and positive to bacterial growth 85 (100) 26 (30.59)a 32 (37.65)a 27 (31.76)a
Microorganism
 Esculin-positive streptococci 77 (90.59) 28 (36.36)a 24 (31.17)a 25 (32.47)a
 Coagulase-positive staphylococci 8 (9.41%) 2 (25)a 3 (37.5)a 3 (37.5)a
a,bDifferent superscript letters within a row indicate significant differences (P < 0.05).
1PC = platelet concentrate.
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In our study, from the random allocation into 3 
groups of the enrolled quarters positive for bacterial 
growth, it is possible to show that the distribution of 
quarters with different bacterial involvement was not 
significantly different among treated groups, with the 
exception of the esculin-positive streptococci group, 
which was less represented in the acute mastitis group 
treated with antibiotic. In addition, from the analysis 
of the average SCC, expressed as LS, the starting LS 
values of the associated treated quarters were the high-
est. In these conditions, our results showed that in all 
treated groups, the average LS decreased significantly 
(P ≤ 0.05) at T30, but in the associated treatment 
group with acute mastitis, the average LS decreased 
to 2.7 points, with a value of SCC <100,000 cells/mL 
of milk in the quarter-milk sample. This value is in ac-
cordance with the definition of a healthy udder quarter 
(Carlén, 2008). In the case of acute mastitis, no statisti-
cally significant differences in the average values of LS 
at T30 were observed between PC-alone- or antibiotic-
alone-treated quarters.
Furthermore, it was demonstrated that the combined 
action of antibiotic and PC performed significantly (P 
≤ 0.05) better than the antibiotic alone with regard 
to clinical improvement of mammary quarters affected 
by mastitis. In the same way, the combined treatment 
gave significantly better results (P ≤ 0.05) compared 
with the antibiotic alone with regard to relapse. The 
percentage of mammary quarters that reached an im-
provement of at least 3 LS points less than the starting 
value of SCC and did not show relapse after treatment 
with antibiotic and PC was significantly higher (P ≤ 
0.05) than the quarters that reached an improvement 
of at least 3 LS points and that showed relapse after 
treatment with the antibiotic alone. These data confirm 
the efficacy of the associated treatment.
Comparing the antibiotic-alone versus the PC-alone 
treatments, the rate of improvement and relapse were 
Table 3. Data relating to the improvement (decrease) in SCC and rate of relapse for each treatment, and clinical distinction between acute 
and chronic mastitis 
Mastitis Treatment1
No. of  
treated  
quarters
Quarters with  
improvement  
of at least  
3 LS points2  
[no. (%)]
Quarters with  
improvement  
<3 LS points  
[no. (%)]
Relapse on quarters  
with improvement  
of at least  
3 LS points  
[no. (%)]
Quarters with  
improvement  
of at least  
3 LS points  
without relapse  
[no. (%)]
Acute Antibiotic 40 21 (52.50)a 19 (47.50)a 9 (42.86)a 12 (57.14)a
PC 51 34 (66.67)a 17 (33.33)a 10 (29.41)a 24 (70.59)a
Antibiotic + PC 53 48 (90.57)b 5 (9.43)b 4 (8.33)b 44 (91.67)b
Chronic Antibiotic 26 4 (15.38)A 22 (84.62)A 4 (100)A 0 (0)A
PC 32 17 (53.13)C 15 (46.87)C 5 (29.41)B 12 (70.59)B
Antibiotic + PC 27 18 (66.67)B 9 (33.33)B 2 (11.11)B 16 (88.89)B
a,bDifferent superscript lowercase letters within a column indicate significant differences (P < 0.05) among treatments in acute mastitis com-
parisons.
A–CDifferent superscript capital letters within a column indicate significant differences (P < 0.05) among treatments in chronic mastitis com-
parisons.
1PC = platelet concentrate.
2LS = linear score.
Table 4. Mean values of the linear scores on d 0, 7, 14, and 30 in acute and chronic mastitis treated with 
different protocols 
Mastitis Treatment1 d 0 d 7 d 14 d 30
Acute Antibiotic 8.61 ± 1.38a,A 6.06 ± 2.50b,A 4.71 ± 2.26c,A 4.70 ± 1.21d,A
PC 8.90 ± 1.09a,A 7.99 ± 1.40a,B 5.83 ± 1.78b,A 4.38 ± 1.21c,A
Antibiotic + PC 10.04 ± 0.87a,B 7.35 ± 2.49a,B 5.06 ± 2.28b,A 2.71 ± 1.41c,B
Chronic Antibiotic 8.40 ± 0.45a,A 6.12 ± 1.44b,A 5.30 ± 1.98c,A 5.28 ± 0.51d,A
PC 8.34 ± 1.59a,A 7.41 ± 1.79a,B 6.37 ± 1.88b,A 5.02 ± 1.23c,A
Antibiotic + PC 9.99 ± 0.73a,B 8.05 ± 1.10b,B 6.02 ± 1.28c,A 4.70 ± 0.44d,B
a–dDifferent superscript lowercase letters within a row (within treatment) indicate significant differences (P ≤ 
0.05) on different days within type of mastitis (acute or chronic). 
A,BDifferent superscript capital letters within a column (within day) indicate significant differences (P ≤ 0.05) 
among treatments within type of mastitis (acute or chronic).
1PC = platelet concentrate.
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not statistically different regarding acute mastitis, but 
it is noteworthy that the treatment with PC alone 
was better than antibiotic alone for chronic mastitis. 
Particularly in the case of chronic mastitis, these find-
ings suggest a possible role of growth factors in tissue 
protection or repair processes, or both (Sheffield, 1997). 
It is known, for example, that the action of TGF-α pro-
motes tissue repair, mammary epithelial proliferation, 
and morphogenesis of the mammary gland (Derynck, 
1992). For this reason, we supposed that an auxiliary 
administration of growth factors, including TGF-α, 
present in PC, can enhance repair of damaged tissue. 
As a prolonged inflammatory response causes tissue 
damage, the PC, contributing to a rapid resolution of 
the inflammatory response, would play a vital role in 
limiting the damage to the host. Platelet concentrate, 
in fact, contains chemokines, some of which act in syn-
ergy with white blood cells, whereas others are chemo-
tactic and able to recall monocytes and macrophages 
at the site of infection. The chemotactic action of PC 
is not limited to mobilize macrophages to the site but 
also to activate them (Marx, 2004). The macrophages, 
attracted by the chemotactic action of growth factors, 
would be able to resolve the inflammation phase, pro-
moting tissue remodeling due to the secretion of factors 
that stimulate the production of fibroblasts (such as 
PDGF), factors that regulate the synthesis of tissue 
connective components (such as TGF-β), and angio-
genic factors (such as vascular endothelial growth fac-
tor). In summary, this therapy is believed to be based 
on the action of both growth factors and chemokines 
released by platelets that act synergistically to increase 
the infiltration of neutrophils and macrophages, pro-
mote angiogenesis, fibroplasia, matrix deposition, and 
re-epithelialization.
Moreover, as no statistically significant differences in 
the average values of LS at T30 were observed between 
PC-only- or antibiotic-only-treated quarters, it is pos-
sible to speculate that PC alone is able, in addition to 
its regenerative properties, to exert also an antibacterial 
effect. Bielecki et al. (2007) described that human PC in 
vitro inhibits the growth of Staphylococcus aureus and 
is also active against Escherichia coli. The α-granules of 
platelets do not only contain growth factors and anti-
microbial peptides, but also catecholamines, serotonin, 
osteonectin, von Willebrand factor, and other substanc-
es that are released in high concentrations after platelet 
aggregation, and many of these factors have antibacte-
rial action. Tang et al. (2002) reported on the isolation 
of and the attempt to identify peptides from platelets 
after stimulation with thrombin and tested the in vitro 
antimicrobial activity of these peptides against Esch-
erichia coli, Staphylococcus aureus, Candida albicans, 
and Cryptococcus neoformans. In the current study, we 
did not evaluate the antimicrobial effects in vitro and 
in vivo of PC using bacteriological tests, but the results 
of the synergic action of PC with antibiotic, and also 
those of PC alone, allow the consideration of reducing 
the dose of antibiotic administered or the use of PC as 
an alternative therapy for mastitis.
In our study, the antibiotic was administered at least 
3 times, as indicated by the manufacturer data sheet. 
But, the obvious reduction of relapses with PC alone 
leads us to believe that the administration of PC alone 
could represent an adequate therapy that could allow 
minimization of the use of antibiotics.
Despite the limited cases, the results obtained by 
PC treatment for chronic mastitis are encouraging, 
as animals affected by chronic mastitis, generally, are 
culled from the herd. If our observations, although 
preliminary, were confirmed in a more extensive study, 
even cows affected by chronic mastitis could return to 
production after adequate treatment with PC.
The element that must always be taken into consid-
eration is that farming is a business enterprise and, in 
the case of mastitis, the goal is not only clinical healing 
but also having the choice of treatment with the best 
cost-benefit ratio, maximizing the production efficiency 
and not focusing exclusively on treatment effectiveness 
(Mazzilli and Zecconi, 2010). The cost of mastitis is 
not only given by the qualitative-quantitative loss of 
milk that occurs during infection (with the consequent 
loss of premium quality for cells and proteins), but also 
by the costs resulting from the interventions required 
every time a case of acute mastitis turns up in the herd.
In this study, it is important to take into account the 
initial economic disadvantage deriving from the use of 
PC in association with antibiotic. During treatment, 
the cost is greater compared with the therapy with an-
tibiotic alone but the effective recovery of the glandular 
tissue without the risk of further treatments due to 
relapse is, in our opinion, worthwhile. In the future, 
the absence of antibiotic residues in milk represents a 
good argument in favor of treatment with PC alone. 
Moreover, PC is a cost-effective and readily available 
therapeutic agent derivable from blood components 
and, once its efficacy is confirmed (in association with 
antibiotic or alone), we could hypothesize an increased 
interest in its application by both veterinarians and 
farmers.
CONCLUSIONS
Our data confirm the hypothesis that PC is involved 
in the healing of mammary tissue in relation to the 
limited rate of relapse. Nevertheless, despite these ad-
vances, it is too early to provide a complete molecular 
explanation for the role of the platelet in the positive 
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evolution of mastitis. The wound healing involves a 
complex and incompletely understood array of molecu-
lar intracellular and extracellular events. It is known 
that platelets play a prominent and likely determinant 
role in the initiation and maintenance of injury healing, 
but further research is required to establish the opti-
mum number of platelets to be used in PC, its efficacy 
in larger clinical trials, and to detect if PC alone could 
markedly influence recovery from mastitis.
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